Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2025 07:30 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
May 14, 2025 16:01 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong...
May 13, 2025 07:30 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
March 31, 2025 07:30 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
February 07, 2025 08:00 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
January 30, 2025 19:30 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop...